Janssen COVID-19 vaccine plant in Baltimore gets Health Canada OK
Advertisement
Read this article for free:
or
Already have an account? Log in here »
To continue reading, please subscribe:
Digital Subscription
One year of digital access for only $205*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*First annual payment billed as $205.00 + GST for one year. This annual subscription will automatically renew at $233.00 + GST every 52 weeks (10% off the regular annual price of $259.35). Offer available to new and qualified returning subscribers only. Cancel any time.
To continue reading, please subscribe:
Add Free Press access to your Brandon Sun subscription for only an additional
$1 for the first 4 weeks*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*Your next Brandon Sun subscription payment will increase by $1.00 and you will be charged $17.95 plus GST for four weeks. After four weeks, your payment will increase to $24.95 plus GST every four weeks.
Read unlimited articles for free today:
or
Already have an account? Log in here »
Hey there, time traveller!
This article was published 24/11/2021 (1704 days ago), so information in it may no longer be current.
OTTAWA – Health Canada has given the green light for Johnson & Johnson COVID-19 vaccines that contained elements produced at the Emergent BioSolutions facility in Baltimore, Md., to be used in Canada, though no shipments are currently planned.
Canada had rejected hundreds of thousands of doses of the vaccine this past summer due to contamination concerns about the plant, and only imported Johnson & Johnson doses, also known as Janssen, manufactured in Europe.
After an on-site inspection of the facility, the regulator has now deemed the facility to be compliant with the necessary quality-assurance practices.
That means Janssen will now be able to import COVID-19 vaccines into Canada that contain drugs manufactured at the Emergent BioSolutions facility.
According to Health Canada, there are no further shipments of the Janssen vaccine planned for now, though the government will work with provinces and territories if they require more supply.
The European Medicines Agency and South African Health Products Regulatory Authority also participated in this inspection remotely and agreed with Canada’s assessment of the facility.
This report by The Canadian Press was first published Nov. 24, 2021.